Feng Qi-Zhu, Chen Xian-Zhi, Sun Jie, Lu Man-Man, Wang Yong, Wang Qi, Zhang Chao
Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Hefei, 230032, Anhui, People's Republic of China.
Department of Breast Surgery, First Affiliated Hospital of Anhui University of Science and Technology (Huainan First People's Hospital), Huainan, 232007, Anhui, People's Republic of China.
Cancer Manag Res. 2021 Oct 27;13:8077-8084. doi: 10.2147/CMAR.S334680. eCollection 2021.
To explore the influence of trastuzumab (TZ) combined with docetaxel (DTX) on serum tumor markers (TMs) in the treatment of human epidermal growth factor receptor 2-positive (HER-2+) breast cancer (BC) and to analyze the factors influencing therapeutic efficacy.
Ninety-six patients with HER-2+ BC treated in the First Affiliated Hospital of Anhui University Of Science and Technology from January 2019 to December 2020 were selected. According to different treatment plans, the patients were divided into two arms with 48 cases each. The control group (CG) was treated with DTX, and the research group (RG) was given TZ combined with DTX (TZ+DTX). The two arms were compared regarding the following aspects: curative effects, adverse reaction, alterations of TMs and inflammatory factors (IFs), and quality of life. Logistic regression analysis was performed to analyze the factors affecting the efficacy of patients.
After treatment, the TMs carcinoembryonic antigen (CEA), carbohydrate antigen (CA)125 and CA15-3 were significantly lower in RG compared with CG. The levels of IFs C-reactive protein (CRP) and tumor necrosis factor-α (TNF-α) were also lower in CG. The overall response rate and the Karnofsky performance status (KPS) score were significantly higher in RG. No evident difference was observed in the total incidence of adverse reactions between the two arms. The high expression of CEA, CA125 and CA15-3 as well as DTX monotherapy increased the risk of adverse prognosis.
TZ+DTX can effectively improve the clinical efficacy of HER-2+ BC patients and reduce their levels of serum TMs and IFs.
探讨曲妥珠单抗（TZ）联合多西他赛（DTX）治疗人表皮生长因子受体2阳性（HER-2+）乳腺癌（BC）对血清肿瘤标志物（TMs）的影响，并分析影响治疗效果的因素。
选取2019年1月至2020年12月在安徽理工大学第一附属医院接受治疗的96例HER-2+ BC患者。根据不同治疗方案，将患者分为两组，每组48例。对照组（CG）接受DTX治疗，研究组（RG）给予TZ联合DTX（TZ+DTX）治疗。比较两组在以下方面的情况：疗效、不良反应、TMs和炎症因子（IFs）的变化以及生活质量。进行Logistic回归分析以分析影响患者疗效的因素。
治疗后，RG组的癌胚抗原（CEA）、糖类抗原（CA）125和CA15-3等TMs水平显著低于CG组。CG组的IFs C反应蛋白（CRP）和肿瘤坏死因子-α（TNF-α）水平也较低。RG组的总缓解率和卡氏功能状态（KPS）评分显著更高。两组不良反应总发生率无明显差异。CEA、CA125和CA15-3的高表达以及DTX单药治疗增加了不良预后的风险。
TZ+DTX可有效提高HER-2+ BC患者的临床疗效，降低其血清TMs和IFs水平。
